Published online Jul 15, 2021. doi: 10.4239/wjd.v12.i7.1026
Peer-review started: February 3, 2021
First decision: March 1, 2021
Revised: April 16, 2021
Accepted: June 16, 2021
Article in press: June 16, 2021
Published online: July 15, 2021
Processing time: 158 Days and 14.3 Hours
The outbreak of coronavirus disease 2019 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). COVID-19 and type 2 diabetes (T2D) have now merged into an ongoing global syndemic that is threatening the lives of millions of people around the globe. For this reason, there is a deep need to understand the immunometabolic bases of the main etiological factors of T2D that affect the severity of COVID-19. Here, we discuss how hyperglycemia contributes to the cytokine storm commonly associated with COVID-19 by stimulating monocytes and macrophages to produce interleukin IL-1β, IL-6, and TNF-α in the airway epithelium. The main mechanisms through which hyperglycemia promotes reactive oxygen species release, inhibition of T cell activation, and neutrophil extracellular traps in the lungs of patients with severe SARS-CoV-2 infection are also studied. We further examine the molecular mechanisms by which proinflammatory cytokines induce insulin resistance, and their deleterious effects on pancreatic β-cell exhaustion in T2D patients critically ill with COVID-19. We address the effect of excess glucose on advanced glycation end product (AGE) formation and the role of AGEs in perpetuating pneumonia and acute respiratory distress syndrome. Finally, we discuss the contribution of preexisting endothelial dysfunction secondary to diabetes in the development of neutrophil trafficking, vascular leaking, and thrombotic events in patients with severe SARS-CoV-2 infection. As we outline here, T2D acts in synergy with SARS-CoV-2 infection to increase the progression, severity, and mortality of COVID-19. We think a better understanding of the T2D-related immunometabolic factors that contribute to exacerbate the severity of COVID-19 will improve our ability to identify patients with high mortality risk and prevent adverse outcomes.
Core Tip: Type 2 diabetes (T2D) acts in synergy with severe acute respiratory syndrome coronavirus-2 infection to increase the progression, severity, and mortality of coronavirus disease 2019 (COVID-19). Thus, the immunometabolic bases of the main etiological factors of T2D that contribute to the severity of COVID-19 should be studied. Here, we discuss the molecular mechanisms by which immune cells, hyperglycemia, hyperinsulinemia, loss of pancreatic β-cell mass, insulin resistance, advanced glycation end products, endothelial dysfunction, and prothrombotic state contribute to the severity of COVID-19. The syndemic between COVID-19 and T2D has challenged our ability to identify patients with high mortality risk based on scientific evidence.